ABCL FY 2021 Earnings — AbCellera Biologics Inc. Revenue & Financial Results | Market Cap Arena

ABCLAbCellera Biologics Inc.

$1B

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$375M+60.9% YoY

Gross Profit

$330M87.9% margin

Operating Income

$204M54.5% margin

Net Income

$153M40.9% margin

EPS (Diluted)

$0.48

Cash Flow

Operating Cash Flow

$245M

Free Cash Flow

$186M

Stock-Based Comp.

$31M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$293M

Stockholders' Equity

$1.0B

Cash & Equivalents

$476M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$375M	$233M	+60.9%
Gross Profit	$330M	$206M	+60.0%
Operating Income	$204M	$156M	+31.0%
Net Income	$153M	$119M	+29.1%